« Back
Home /
Tacrolimus (monohydrate)

Tacrolimus (monohydrate)

Item no.	HY-13756A-5mg
Manufacturer	MedChem Express
CASRN	109581-93-3
Amount	5 mg
Quantity options	10mM/1mL 10 mg 50 mg 5 mg
Category	Food Safety Drugs Histamines Hormones Neuroscience Metabolism Cholesterol & Lipid Metabolism Neural Signaling Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.67
Formula	C44H71NO13
Citations	Fundamental Research. 2024 Mar 19.<br/>SSRN. 2023 Oct 31.<br/>Acs Biomater Sci Eng. 2022 Oct 10.<br/>Acta Pharmacol Sin. 2024 May 17.<br/>Acta Trop. 2020 Dec;212:105708.<br/>Adv Funct Mater. 2023 Sep 15.<br/>Aging Dis. 2023 Jun 6.<br/>Am J Digest Dis. 2015;2(2):95-99.<br/>Am J Transplant. 2022.<br/>Animal Model Exp Med. 2022 Sep 21.<br/>Antiviral Res. 2023 May 2;105618.<br/>Biochim Biophys Acta Gen Subj. 2022 Jun;1866(6):130133.<br/>Biomater Sci. 2020 Oct 7;8(19):5282-5292.<br/>Biomater Sci. 2023 May 2.<br/>Biomaterials. 2021, 120757.<br/>Biomolecules. 2024 Jun 08.<br/>BMC Immunol. 2023 Nov 8;24(1):43.<br/>BMC Pharmacol Toxicol. 2022 Nov 28;23(1):87.<br/>Br J Pharmacol. 2022 Jan 20.<br/>Brain Res. 2019 May 15;1711:68-76.<br/>Cancer Lett. 2024 Apr 11:216841.<br/>Cell Biol Toxicol. 2022 Jun;38(3):487-504.<br/>Cell Commun Signal. 2021 Oct 11;19(1):103.<br/>Cell Mol Biol Lett. 2024 May 14;29(1):72.<br/>Cell Prolif. 2023 Mar 27;e13460.<br/>Cell Rep. 2021 Apr 6;35(1):108959.<br/>Cell Rep. 2021 Jul 20;36(3):109404.<br/>Cell Syst. 2018 Apr 25;6(4):424-443.e7.<br/>Dis Model Mech. 2019 Jan 28;12(1). pii: dmm036830. <br/>Drug Deliv. 2021 Dec;28(1):1759-1768.<br/>Elife. 2023 MAy 19.<br/>Exp Hematol Oncol. 2016 Jul 29;5:22. <br/>FASEB J. 2023 Feb;37(2):e22749.<br/>Food Funct. 2023 Jul 3.<br/>Hepatobiliary Pancreat Dis Int. 2023 Aug 22.<br/>Hepatobiliary Surg Nutr. 2023 Feb 27.<br/>Hong Kong Polytechnic University. 2023 Apr.<br/>Insect Sci. 2023 Oct 12.<br/>Int J Mol Sci. 2022 Aug 19;23(16):9376.<br/>Int J Mol Sci. 2024 Feb 21, 25(5), 2503.<br/>Int J Pharm. 2019 Dec 13;575:118951. <br/>Int J Physiol Pathophysiol Pharmacol. 2015 Mar 20;7(1):54-60. <br/>Invest Ophthalmol Vis Sci. 2023 Jan 3;64(1):19.<br/>J Cell Sci. 2019 May 20;132(10):jcs227777.<br/>J Colloid Interface Sci. 5 October 2022.<br/>J Control Release. 2020 Dec 10;328:237-250.<br/>J Extracell Vesicles. 2019 Dec 27;9(1):1709262.<br/>J Neurochem. 2022 Oct 21.<br/>J Pharm Biomed Anal. 2023 Aug 19, 115652.<br/>J Vet Med Sci. 2023 Feb 17.<br/>Mater Design. 2023 Nov, 235, 112415.<br/>Mater Today Bio. 2024 Apr 22:101061.<br/>Mediat Inflamm. 2019 Dec 17;2019:4176974.<br/>Mol Med Rep. 2022 May;25(5):160.<br/>Nano Lett. 2019 Jan 9;19(1):124-134.<br/>Nano Res. 11, 6086-6101(2018).<br/>NPJ Regen Med. 2022 Sep 2;7(1):43.<br/>Patent. US20180263995A1.<br/>Patent. US20220087984A1.<br/>Pharmacol Res. 2021, 105382.<br/>Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118.<br/>Research Square Preprint. 2020 Dec.<br/>Signal Transduct Target Ther. 2023 Nov 1;8(1):417.<br/>Skelet Muscle. 2020 Apr 22;10(1):10.<br/>Theranostics. 2018 Jan 1;8(4):878-893.<br/>Theranostics. 2020 May 16;10(14):6483-6499. <br/>Theranostics. 2021 Mar 5;11(10):5045-5060.<br/>Theranostics. 2022 Jan 16;12(4):1621-1638.<br/>Toxins (Basel). 2019 Jun 18;11(6):349.<br/>Transpl Immunol. 2021 Jun 30;101434.<br/>Ultrasound Med Biol. 2023 Apr 27;S0301-5629(23)00108-4.<br/>Wound Repair Regen. 2023 May 2.<br/>[1]Thomson AW, et al. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.<br/>[2]Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016 Nov;39(6):877-886.<br/>[3]Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α expression in vivo. Mol Med Rep. 2014 Aug;10(2):585-92.<br/>[4]Okada Y, et al. Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interferon-γ and interleukin-1β suppression. Biol Pharm Bull. 2011;34(12):1823-7.
Smiles	O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O.O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	FK506 (monohydrate); Fujimycin (monohydrate); FR900506 (monohydrate)
Available
Product Description	Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	822.03
Clinical Information	Launched
Manufacturers Research Area	Cancer; Infection; Inflammation/Immunology
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Target	Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase
Manufacturers Target	Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase
Isoform	Macrolide
Manufacturers Pathway	Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease
Manufacturers Product type	Natural Products

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13756A-5mg-safety-datasheet.pdf